209 related articles for article (PubMed ID: 24826982)
1. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
2. Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.
Tseng SH; Park ST; Lam B; Tsai YC; Cheng MA; Farmer E; Xing D; Hung CF
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111730
[TBL] [Abstract][Full Text] [Related]
3. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.
Wobser M; Voigt H; Houben R; Eggert AO; Freiwald M; Kaemmerer U; Kaempgen E; Schrama D; Becker JC
Cancer Immunol Immunother; 2007 Jul; 56(7):1017-24. PubMed ID: 17195079
[TBL] [Abstract][Full Text] [Related]
5. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.
Nakamura T; Shima T; Saeki A; Hidaka T; Nakashima A; Takikawa O; Saito S
Cancer Sci; 2007 Jun; 98(6):874-81. PubMed ID: 17433037
[TBL] [Abstract][Full Text] [Related]
6. Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
Asem M; Young AM; Oyama C; Claure De La Zerda A; Liu Y; Yang J; Hilliard TS; Johnson J; Harper EI; Guldner I; Zhang S; Page-Mayberry T; Kaliney WJ; Stack MS
Cancer Res; 2020 Mar; 80(5):1156-1170. PubMed ID: 31932454
[TBL] [Abstract][Full Text] [Related]
7. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Awuah SG; Zheng YR; Bruno PM; Hemann MT; Lippard SJ
J Am Chem Soc; 2015 Dec; 137(47):14854-7. PubMed ID: 26561720
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of IDO gene expression reduces the immunogenicity of epidermal cells and strengthens the immune protection of epidermal cells during transplantation treatment of wounds.
Zhang K; Liu X; Luo P; Li Z; Zhao H; Li D; Liu Z; Zhang B; Shen C
Transpl Immunol; 2024 Feb; 82():101987. PubMed ID: 38218230
[TBL] [Abstract][Full Text] [Related]
9. IDO is a nodal pathogenic driver of lung cancer and metastasis development.
Smith C; Chang MY; Parker KH; Beury DW; DuHadaway JB; Flick HE; Boulden J; Sutanto-Ward E; Soler AP; Laury-Kleintop LD; Mandik-Nayak L; Metz R; Ostrand-Rosenberg S; Prendergast GC; Muller AJ
Cancer Discov; 2012 Aug; 2(8):722-35. PubMed ID: 22822050
[TBL] [Abstract][Full Text] [Related]
10. Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment.
Zhou C; Zhang Y; Yan R; Huang L; Mellor AL; Yang Y; Chen X; Wei W; Wu X; Yu L; Liang L; Zhang D; Wu S; Wang W
Cell Death Differ; 2021 Feb; 28(2):715-729. PubMed ID: 32929219
[TBL] [Abstract][Full Text] [Related]
11. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry.
Nguyen TT; Shin DH; Sohoni S; Singh SK; Rivera-Molina Y; Jiang H; Fan X; Gumin J; Lang FF; Alvarez-Breckenridge C; Godoy-Vitorino F; Zhu L; Zheng WJ; Zhai L; Ladomersky E; Lauing KL; Alonso MM; Wainwright DA; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902132
[TBL] [Abstract][Full Text] [Related]
12. The role of the indoleamine 2,3-dioxygenase gene in preventing ovarian transplant rejection in rats.
Long A; Zhao S; Huang G; Li X; Cheng H; Chen Z; Hu Z; Zhu L; Zhao D; Hu X; Wang J
Biol Reprod; 2024 Mar; ():. PubMed ID: 38452209
[TBL] [Abstract][Full Text] [Related]
13. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation.
Levina V; Su Y; Gorelik E
Clin Dev Immunol; 2012; 2012():173029. PubMed ID: 22654951
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Multiplexed Analysis of Indoleamine 2,3-Dioxygenase (IDO) and Arginase-1 (ARG1) Expression and Myeloid Cell Infiltration in Colorectal Cancer.
Elomaa H; Härkönen J; Väyrynen SA; Ahtiainen M; Ogino S; Nowak JA; Lau MC; Helminen O; Wirta EV; Seppälä TT; Böhm J; Mecklin JP; Kuopio T; Väyrynen JP
Mod Pathol; 2024 Apr; 37(4):100450. PubMed ID: 38369188
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Sosman JA; Zhang B; Wu JD; Miller SD; Meeks JJ; Lukas RV; Wyatt E; Doglio L; Schiltz GE; McCusker RH; Wainwright DA
Front Immunol; 2020; 11():1185. PubMed ID: 32612606
[TBL] [Abstract][Full Text] [Related]
16. Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites.
Hrvat A; Schmidt M; Wagner B; Zwanziger D; Kimmig R; Volbracht L; Brandau S; Mallmann-Gottschalk N
J Exp Clin Cancer Res; 2023 Sep; 42(1):235. PubMed ID: 37684704
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cancer-specific immune responses by amino acid degrading enzymes.
Timosenko E; Hadjinicolaou AV; Cerundolo V
Immunotherapy; 2017 Jan; 9(1):83-97. PubMed ID: 28000524
[TBL] [Abstract][Full Text] [Related]
18. IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy.
Park J; Nah Y; Kim WJ
J Control Release; 2023 Nov; 363():496-506. PubMed ID: 37788761
[TBL] [Abstract][Full Text] [Related]
19. Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells.
Chen RR; Yung MMH; Xuan Y; Zhan S; Leung LL; Liang RR; Leung THY; Yang H; Xu D; Sharma R; Chan KKL; Ngu SF; Ngan HYS; Chan DW
Commun Biol; 2019; 2():281. PubMed ID: 31372520
[TBL] [Abstract][Full Text] [Related]
20. Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity.
Steinkamp MP; Lagutina I; Brayer KJ; Schultz F; Burke D; Pankratz VS; Adams SF; Hudson LG; Ness SA; Wandinger-Ness A
Cancer Res Commun; 2023 Feb; 3(2):309-324. PubMed ID: 36860657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
